HC Wainwright Issues Positive Estimate for argenx Earnings

argenx SE (NASDAQ:ARGX - Free Report) - Analysts at HC Wainwright lifted their Q3 2025 earnings estimates for shares of argenx in a report released on Friday, February 28th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of $1.68 for the quarter, up from their prior forecast of $1.65. HC Wainwright currently has a "Buy" rating and a $720.00 price objective on the stock. The consensus estimate for argenx's current full-year earnings is $3.13 per share. HC Wainwright also issued estimates for argenx's FY2025 earnings at $6.50 EPS.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million.

Several other research analysts have also commented on the stock. Piper Sandler raised their price target on shares of argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a report on Tuesday, January 7th. William Blair reissued an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Robert W. Baird upped their price target on shares of argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research report on Tuesday. JMP Securities increased their price target on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Finally, Oppenheimer boosted their price objective on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, argenx currently has an average rating of "Moderate Buy" and a consensus target price of $662.83.

Remove Ads

argenx Trading Down 3.7 %

Shares of argenx stock traded down $23.31 during trading hours on Monday, reaching $613.18. The stock had a trading volume of 167,636 shares, compared to its average volume of 281,597. The firm has a market capitalization of $37.26 billion, a price-to-earnings ratio of -696.80 and a beta of 0.58. argenx has a 1 year low of $349.86 and a 1 year high of $678.21. The firm has a 50 day simple moving average of $642.47 and a two-hundred day simple moving average of $592.89.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Stifel Financial Corp lifted its position in shares of argenx by 15.3% during the third quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock worth $4,788,000 after purchasing an additional 1,170 shares during the last quarter. FMR LLC raised its stake in argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company's stock valued at $2,598,445,000 after buying an additional 1,265,486 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in argenx by 64.0% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock worth $1,311,000 after buying an additional 944 shares during the last quarter. Stephens Inc. AR acquired a new position in shares of argenx in the 4th quarter worth approximately $310,000. Finally, Ritholtz Wealth Management increased its holdings in shares of argenx by 85.5% in the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after acquiring an additional 414 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.